Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The FDA’s January 2025 approval of Journavx (suzetrigine), a non-opioid oral pain treatment, further contributed to the company’s market capitalisation growth. Gilead Sciences witnessed a ...

Vertex received FDA approval for JOURNAVX™ (suzetrigine), a novel, non-addictive treatment for moderate-to-severe acute pain – marking a key milestone in its expansion beyond cystic fibrosis.

The frontrunner at the moment is Vertex Pharma, whose NaV1.8 inhibitor suzetrigine (formerly VX-548) has already been filed for approval in the US for two moderate-to-severe acute pain indications ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...